NYSE:TAK - Takeda Pharmaceutical Stock Price, Forecast & News

Takeda Pharmaceutical's stock was trading at $17.15 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TAK stock has decreased by 8.9% and is now trading at $15.63. View which stocks have been mosted impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Takeda Pharmaceutical in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Takeda Pharmaceutical.

Takeda Pharmaceutical is scheduled to release its next quarterly earnings announcement on Tuesday, May 12th 2020. View our earnings forecast for Takeda Pharmaceutical.

Takeda Pharmaceutical Co Ltd (NYSE:TAK) released its quarterly earnings results on Tuesday, February, 4th. The company reported $0.53 earnings per share (EPS) for the quarter. The business earned $7.90 billion during the quarter. Takeda Pharmaceutical had a net margin of 2.25% and a return on equity of 13.17%. View Takeda Pharmaceutical's earnings history.

Takeda Pharmaceutical issued an update on its FY 2019 Pre-Market earnings guidance on Tuesday, February, 4th. The company provided earnings per share (EPS) guidance of 3.53-3.72 for the period. The company issued revenue guidance of $30.147-30.147 billion.

4 equities research analysts have issued 12 month target prices for Takeda Pharmaceutical's shares. Their forecasts range from $19.50 to $30.00. On average, they expect Takeda Pharmaceutical's share price to reach $24.75 in the next year. This suggests a possible upside of 58.3% from the stock's current price. View analysts' price targets for Takeda Pharmaceutical.

Media stories about TAK stock have trended very negative on Monday, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Takeda Pharmaceutical earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutTakeda Pharmaceutical.

Some companies that are related to Takeda Pharmaceutical include Merck & Co., Inc. (MRK), Novartis (NVS), Pfizer (PFE), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), AstraZeneca (AZN), AbbVie (ABBV), Sanofi (SNY), GlaxoSmithKline (GSK), Commonwealth Bank of Australia (CSLLY), Celgene (CELG), Allergan (AGN) and Vertex Pharmaceuticals (VRTX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Takeda Pharmaceutical investors own include Alibaba Group (BABA), Verizon Communications (VZ), Cisco Systems (CSCO), Walt Disney (DIS), Honeywell International (HON), Johnson & Johnson (JNJ), Home Depot (HD), AT&T (T), CVS Health (CVS) and NVIDIA (NVDA).

Takeda Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "TAK."

Takeda Pharmaceutical's stock is owned by a variety of retail and institutional investors. Top institutional investors include Adelphi Capital LLP (0.29%), Macquarie Group Ltd. (0.16%), Macquarie Group Ltd. (0.16%), Bank of America Corp DE (0.13%), First Trust Advisors LP (0.07%) and Renaissance Technologies LLC (0.06%).

TAK stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, LMR Partners LLP, UBS Asset Management Americas Inc., TIG Advisors LLC, Janus Henderson Group PLC, Macquarie Group Ltd., Macquarie Group Ltd., and Franklin Resources Inc..

TAK stock was purchased by a variety of institutional investors in the last quarter, including Ovata Capital Management Ltd, Renaissance Technologies LLC, Raymond James & Associates, TD Asset Management Inc., Blueshift Asset Management LLC, Van ECK Associates Corp, Eagle Global Advisors LLC, and Magnetar Financial LLC.

Shares of TAK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of TAK stock can currently be purchased for approximately $15.63.

Takeda Pharmaceutical has a market capitalization of $49.28 billion and generates $18.88 billion in revenue each year. The company earns $982.13 million in net income (profit) each year or $0.51 on an earnings per share basis. Takeda Pharmaceutical employs 49,578 workers across the globe. View additional information about Takeda Pharmaceutical.

The official website for Takeda Pharmaceutical is http://www.takeda.com/.

Takeda Pharmaceutical's mailing address is 1-1 Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo M0, 103-8668. The company can be reached via phone at 813-3278-2306.